HPB 092
Alternative Names: HPB-092Latest Information Update: 02 Jun 2023
At a glance
- Originator Polymed Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 14 Apr 2023 Preclinical trials in Acute myeloid leukaemia in China (PO) before April 2023
- 14 Apr 2023 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical trial in Acute myeloid leukaemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)